|
The doctor complained to the distributor that he was using company¿s known dressing for at least eight years.He mentioned that in the last three months of treating a patient at known hospital, he and his colleagues had found that company¿s known dressing, no longer had the hemostatic quality which it earlier had.Their patient had bad soakage of their dressings overnight in spite of heavy padding dressing over the company¿s known dressing.The duration of use was average of 12 hours, less than 24 hours.The wound was donor area, and the patient was not on anticoagulants.No photo is available at this time.
|
|
E1: complainant city: (b)(6).Complainant country: united arab emirates.Hospital name: (b)(6).Name of affiliation: (b)(6).It was also reported that there were twelve patients involved.Hence, separate reports are being submitted for the other patients involved.Based on the available information, this event is deemed to be a reportable malfunction.To date no additional information has been received.Should additional information become available, a follow-up report will be submitted.Fda registration number reporting site: 1049092.Manufacturing site: 1000317571.
|
|
A batch record review was completed and no discrepancies were found.Kaltostat drs wt 10x20cm 1x10pk ster eur was manufactured under system application product (sap) code 1226579 and manufacturing lot number 2m00714 on 10 december 2022.Lot # 2m00714 was sterilized under reference (b)(4) and released on review of results of sterilization provided by sterilization company steris.All of the results were within specification and products were released.No nonconformity was identified during the manufacturing process of lot 2m00714.This is the only complaint for this affected lot number in database.This complaint is related to 11 other complaints, as noted above, received from the same complainant.This complaint is for an absorption issue with a single patient.Parent case is for absorption issue with kaltostat (patient 1).Sister cases are absorption issue with kaltostat (patient 2), absorption issue with kaltostat (patient 3), absorption issue with kaltostat (patient 4), absorption issue with kaltostat (patient 5), absorption issue with kaltostat (patient 6), absorption issue with kaltostat (patient 7), absorption issue with kaltostat (patient 8), absorption issue with kaltostat (patient 9), absorption issue with kaltostat (patient 10), absorption issue with kaltostat (patient 11) and absorption issue with kaltostat (patient 12).No photographs were received for this issue, so could not be evaluated in accordance with work instructions (wi).Samples were requested from the known batch, which were initially available, but were not received at the same times as the related samples from lot 3d01546 and lot 2f02855.As the samples were not received, it was not possible to confirm the complaint or identify if the complaint is justified.As no images were received and no samples were received for this known batch, it was not possible to fully investigate the absorbency issue associated with this batch.Unused samples from the related known batches (3d01546 and 2f02855) were received, and following laboratory testing against the product specifications for absorbency, the dressings were confirmed to be within specification.As it was not possible to substantiate the complaint or complete testing for this known batch, there was no evidence of nonconformance against the specification.No corrective action / preventive actions (capa) or non-conformance (nc) was raised for the issue.This issue will be monitored through the post market product monitoring review process.To date no additional information has been received.Should additional information become available, a follow-up report will be submitted.Fda registration number reporting site: 1049092 manufacturing site: 1000317571.
|